Ozempic in Dubai
Semaglutide availability, pharmacy pricing, shortage status, and research-grade alternatives. Compare Ozempic with next-generation multi-receptor compounds available in the UAE.
Ozempic is Novo Nordisk’s branded semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes and widely used off-label for weight loss. In Dubai, Ozempic faces persistent supply shortages with pharmacy stock unpredictable and clinic pricing at AED 1,500–4,000+ per month. Research-grade semaglutide is available for laboratory use, but researchers are increasingly studying next-generation compounds like tirzepatide (22.5% weight loss) and retatrutide (24.2%) that surpass Ozempic’s single-receptor mechanism.
Retatrutide pen 30mg (3 receptors vs Ozempic’s 1, 24.2% weight loss data). 99.262% HPLC purity. 2-hour Dubai delivery.
What Is Ozempic?
Ozempic is the brand name for semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist manufactured by Novo Nordisk. It was originally approved for type 2 diabetes management but has become one of the most widely prescribed weight-loss medications globally due to its appetite-suppressing effects.
Ozempic is administered as a once-weekly subcutaneous injection at doses of 0.25mg, 0.5mg, or 1mg. The same semaglutide molecule is also available as Wegovy (2.4mg, approved for weight management) and Rybelsus (oral tablet for diabetes). For a complete comparison of semaglutide formats, see our semaglutide Dubai guide.
Ozempic Availability in Dubai
Current Shortage Status
Ozempic availability in Dubai has been intermittent since 2023 due to global manufacturing constraints at Novo Nordisk. Demand driven by off-label weight loss use far exceeds production capacity. Dubai pharmacies experience unpredictable stock, with wait times of 2–6 weeks common. Some pharmacies impose purchase limits when stock arrives.
For a detailed analysis of the shortage causes and projected resolution timeline, see our Ozempic shortage in Dubai guide.
Pharmacy Pricing
When available, Ozempic in Dubai pharmacies costs AED 800–1,500+ per pen depending on dose. Clinic weight-loss programmes prescribing Ozempic charge AED 1,500–4,000+ per month including consultation, monitoring, and the medication. Insurance coverage for weight-loss use is inconsistent across UAE providers.
Research-Grade Semaglutide
Research-grade semaglutide is available in Dubai for in-vitro laboratory use without the supply constraints affecting branded Ozempic. Remy Peptides provides HPLC-verified semaglutide with published COA documentation. For current pricing and formats, contact us via WhatsApp.
Ozempic vs Wegovy vs Rybelsus
All three brands contain semaglutide but differ in dose, route, and approved indication:
| Brand | Dose | Route | Indication |
|---|---|---|---|
| Ozempic | 0.25–1 mg/week | Subcutaneous | Type 2 diabetes |
| Wegovy | 2.4 mg/week | Subcutaneous | Weight management |
| Rybelsus | 3–14 mg/day | Oral tablet | Type 2 diabetes |
Wegovy’s higher dose (2.4mg vs Ozempic’s max 1mg) is the key difference for weight loss research. The STEP 1 trial using 2.4mg semaglutide showed 14.9% mean body weight reduction over 68 weeks. For researchers comparing semaglutide with next-generation compounds, see our Ozempic alternatives in Dubai guide.
Why Researchers Look Beyond Ozempic
Ozempic’s single-receptor mechanism (GLP-1 only) represents first-generation incretin therapy. While effective, it has inherent limitations that next-generation compounds address:
- Single receptor: GLP-1 only. No GIP or glucagon receptor activation, limiting metabolic scope
- Weight loss ceiling: ~15% in STEP trials, surpassed by dual and triple agonists
- No energy expenditure increase: Semaglutide reduces appetite but does not increase basal metabolic rate
- Muscle mass concern: Up to 40% of weight lost on GLP-1 monotherapy may be lean mass
Multi-receptor compounds address these limitations. Tirzepatide adds GIP receptor activation (22.5% weight loss). Retatrutide adds both GIP and glucagon receptors (24.2% weight loss), with the glucagon component increasing energy expenditure and hepatic lipid oxidation. For the full pipeline analysis, see our best obesity drug 2026 report.
Research-Grade Alternatives
For researchers studying incretin-based mechanisms, the available research-grade compounds offer distinct advantages:
| Compound | Receptors | Weight Loss | Availability |
|---|---|---|---|
| Semaglutide (Ozempic molecule) | GLP-1 (1) | ~15% | Research-grade available |
| Tirzepatide | GLP-1 + GIP (2) | ~22.5% | Research-grade available |
| Retatrutide | GLP-1 + GIP + glucagon (3) | 24.2% | In stock — HPLC verified |
Research-grade compounds provide advantages over branded pharmaceuticals for laboratory use: HPLC purity verification, published COA documentation that branded products do not provide, consistent availability without shortage constraints, and competitive pricing. All Remy Peptides compounds are verified at ≥99% purity. See our COA documentation.
Delivery Across the UAE
- Dubai: 2-hour delivery — all areas
- Abu Dhabi: Next-day delivery
- Sharjah & other emirates: Next-day delivery
All shipments use temperature-controlled packaging. Contact us via WhatsApp at +34 672 737 521 for ordering and availability.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and published clinical trial data. Read our editorial policy →
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Revised 2024.
- Jastreboff AM, et al. Retatrutide Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
Retatrutide Pen 30 mg
Next-generation triple agonist. 24.2% weight loss data. 99.262% HPLC purity. 2-hour Dubai delivery.
Order Retatrutide Pen →